Cti Biopharma Quick Ratio (CTIC) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cti Biopharma Corp   (NASDAQ: CTIC)

Cti Biopharma 's Quick Ratio

CTIC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 0.86 below Cti Biopharma 's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Cti Biopharma in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 1850 to 2054.

Explain Quick Ratio?
How much Cash & cash equivalents CTIC´s has?
What are CTIC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CTIC Quick Ratio (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4		 (Sep 30 2022)
Q3		 (Jun 30 2022)
Q2		 (Mar 31 2022)
Q1
Y / Y Current Liabilities Change -31.04 % 19.56 % -52.25 % 88.67 % 535.89 %
Y / Y Cash & cash equivalent Change -39.1 % 22.14 % -14.31 % 33.37 % 160.73 %
Quick Ratio MRQ 0.86 0.99 2.74 3.22 0.98
CTIC's Total Ranking # 2054 # 1850 # 1195 # 1016 # 1856
Seq. Current Liabilities Change -15.91 % 172.54 % -0.06 % -69.89 % 45.79 %
Seq. Cash & cash equivalent Change -26.18 % -2.08 % -14.84 % -1.06 % 48.06 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 792
Overall Market # 2054


Quick Ratio Statistics
High Average Low
5.63 2.29 0.44
(Mar 31 2020)   (Jun 30 2012)




Financial Statements
Cti Biopharma 's Current Liabilities $ 68 Millions Visit CTIC's Balance sheet
Cti Biopharma 's Cash & cash equivalent $ 59 Millions Visit CTIC's Balance sheet
Source of CTIC's Sales Visit CTIC's Sales by Geography


Cumulative Cti Biopharma 's Quick Ratio

CTIC's Quick Ratio for the trailling 12 Months

CTIC Quick Ratio

 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months		 (Sep 30 2022)
12 Months		 (Jun 30 2022)
12 Months		 (Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -14.7 % 48.33 % 104.42 % 311.62 % 302.44 %
Y / Y Cash & cash equivalent TTM Growth -3.96 % 31.35 % 32.36 % 61.48 % 51.75 %
Quick Ratio TTM 1.51 1.48 1.5 1.37 1.35
Total Ranking TTM # 4439 # 640 # 4396 # 4459 # 4451
Seq. Current Liabilities TTM Growth -12.81 % 5.86 % -12.58 % 5.72 % 51.61 %
Seq. Cash & cash equivalent TTM Growth -10.69 % 4.26 % -3.86 % 7.28 % 22.14 %

Quick ratio ranking by company, industry and sector >> Back to CTIC Financial Strength Comparisons >> Go to Compare CTIC Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Cti Biopharma 's average Cash & cash equivalent, this led to increase in in Cti Biopharma 's Quick Ratio to 1.51, Quick Ratio remained below CTIC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 584 other companies have achieved higher Quick Ratio than Cti Biopharma . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 640 to 4439.

Explain Quick Ratio?
How much Cash & cash equivalents CTIC´s has?
What are CTIC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 585
Healthcare Sector # 1161
Within the Market # 4439


trailing twelve months Quick Ratio Statistics
High Average Low
4.37 2.34 1.27
(Dec 31 2020)   (Mar 31 2017)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Apollomics Inc   2.36 $ 32.056  Millions$ 13.556  Millions
Legend Biotech Corporation  2.29 $ 660.050  Millions$ 288.531  Millions
Actinium Pharmaceuticals Inc  2.23 $ 94.522  Millions$ 42.358  Millions
Precigen Inc   2.23 $ 104.091  Millions$ 46.733  Millions
Tg Therapeutics Inc   2.21 $ 139.710  Millions$ 63.076  Millions
Vtv Therapeutics Inc   2.20 $ 18.781  Millions$ 8.532  Millions
Hutchmed china Limited  2.20 $ 886.336  Millions$ 403.027  Millions
Curevac N v   2.19 $ 456.571  Millions$ 208.756  Millions
Revelation Biosciences Inc   2.19 $ 17.703  Millions$ 8.101  Millions
Benitec Biopharma Inc   2.09 $ 6.576  Millions$ 3.153  Millions
Ardelyx inc   2.07 $ 130.373  Millions$ 63.063  Millions
Mannkind Corporation  2.03 $ 166.142  Millions$ 81.853  Millions
Maia Biotechnology Inc   2.01 $ 7.586  Millions$ 3.766  Millions
Oculis Holding Ag  2.01 $ 45.600  Millions$ 22.710  Millions
Monopar Therapeutics Inc   1.98 $ 5.726  Millions$ 2.888  Millions
Immunogen inc   1.98 $ 201.249  Millions$ 101.629  Millions
Eton Pharmaceuticals Inc   1.96 $ 14.708  Millions$ 7.494  Millions
Equillium Inc   1.96 $ 61.992  Millions$ 31.616  Millions
Biovie Inc   1.95 $ 31.276  Millions$ 16.004  Millions
Universe Pharmaceuticals Inc  1.95 $ 18.504  Millions$ 9.505  Millions
Sigilon Therapeutics Inc   1.94 $ 56.369  Millions$ 28.989  Millions
Amicus Therapeutics inc   1.93 $ 267.109  Millions$ 138.385  Millions
Biomarin Pharmaceutical Inc  1.93 $ 1,152.091  Millions$ 598.231  Millions
Taro Pharmaceutical Industries Ltd  1.89 $ 730.309  Millions$ 385.548  Millions
Amphastar Pharmaceuticals Inc   1.85 $ 195.092  Millions$ 105.635  Millions
Cellectar Biosciences Inc   1.84 $ 12.683  Millions$ 6.905  Millions
Adlai Nortye Ltd  1.82 $ 91.492  Millions$ 50.317  Millions
Acadia Pharmaceuticals Inc   1.80 $ 402.873  Millions$ 224.301  Millions
Alzamend Neuro Inc   1.79 $ 5.141  Millions$ 2.870  Millions
Immunome Inc   1.79 $ 44.424  Millions$ 24.831  Millions

Date modified: 2026-09-08T15:10:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.